Pharma Penetration Testing: Protecting Research, Trials and Manufacturing

Quick answer: Pharma penetration testing is an authorized, controlled security test of the systems pharmaceutical companies rely on, such as research and lab systems, clinical trial platforms, manufacturing and quality systems, supply chain and serialization tools, and corporate IT. Qualified testers safely try to exploit weaknesses the way a real attacker would, then explain the impact and how to fix it. Testing helps protect intellectual property and patient data, keeps validated GxP systems trustworthy and reduces the risk of ransomware stopping production.

Pharmaceutical companies are among the most valuable targets in any industry. Drug research represents years of investment, clinical trials involve sensitive participant data, and manufacturing plants must keep running to supply patients. Attackers range from ransomware groups seeking a fast payout to well-funded actors seeking research data. At the same time, regulators expect electronic records to be accurate and protected, and partners expect strong security across the supply chain.

This guide explains why pharma companies need testing, which regulations and expectations apply, how to test validated and manufacturing environments safely and how to choose a testing partner. To discuss testing for your organization, explore Privaxi's healthcare and life sciences cybersecurity services.

What Is Pharma Penetration Testing?

Pharma penetration testing applies standard penetration testing methods to the research, clinical, manufacturing and business environments of pharmaceutical and biotech companies. Unlike an automated vulnerability scan, it shows how weaknesses could be chained into a real attack, for example how a phished researcher's account could lead to an electronic lab notebook, a clinical data system or the network connecting to a manufacturing site. The result is a prioritized list of findings with clear remediation guidance.

For a general introduction, see our guide to penetration testing services and our overview of types of penetration testing.

Why Pharmaceutical Companies Are Targeted

• Valuable intellectual property: compound data, formulations, trial results and regulatory submissions.

• Sensitive clinical data: trial participant information and health data across many countries.

• Production pressure: downtime at a plant can disrupt supply to patients, which raises ransom pressure.

• Complex partner networks: contract research organizations, contract manufacturers, distributors and academic partners all connect to company systems.

• Mixed technology: modern cloud platforms sit alongside lab instruments and manufacturing systems that are hard to patch.

• High-profile events: mergers, product launches and public health events attract attention from attackers.

Regulations and Expectations That Drive Testing

These rules do not all name penetration testing, but regular pharma penetration testing is one of the most practical ways to show that access controls, audit trails and data protections actually work. Partners, insurers and investors increasingly ask for testing evidence too. Confirm specific obligations with your quality, regulatory and legal teams. For related guidance, see HIPAA penetration testing and healthcare penetration testing.

What to Include in Scope

• Internet-facing systems: websites, partner portals, remote access and VPNs. See external penetration testing.

• Corporate network: workstations, servers, Active Directory and segmentation between business, research and manufacturing networks. See internal penetration testing.

• Research systems: electronic lab notebooks, laboratory information management systems, research data stores and high-performance computing.

• Clinical systems: electronic data capture, clinical trial management, patient-facing apps and portals. See web application penetration testing and mobile application penetration testing.

• Quality and manufacturing systems: quality management, manufacturing execution and related systems, tested carefully and often in non-production environments.

• Supply chain and serialization: serialization platforms, ERP and data exchange with trading partners.

• Cloud environments: cloud research platforms, data lakes and SaaS applications. See cloud penetration testing.

• APIs and partner connections: integrations with CROs, CMOs, distributors and labs. See API penetration testing and third-party penetration testing.

• Connected devices: lab instruments and connected equipment. See IoT penetration testing.

Start with the data and systems that matter most: research IP, clinical data and the systems that keep production running. Our guide to penetration testing scope explains how to prioritize.

Testing Validated GxP Systems Safely

Validated systems need extra care. Any testing that could change configuration, data or performance must be planned with quality assurance so the system stays in a validated state. Good practice includes:

1. Involving QA and system owners early and documenting testing under change control where required.

2. Testing validated systems in qualified test or staging environments that mirror production when possible.

3. Agreeing what testers may and may not do on production systems, such as read-only access checks.

4. Avoiding any action that could create, modify or delete GxP records.

5. Recording evidence of testing activity so it can be reviewed during inspections.

6. Planning remediation through normal change control and revalidation processes.

With the right planning, pharma penetration testing strengthens data integrity instead of putting it at risk.

Manufacturing and Operational Technology

Manufacturing sites often connect business networks to operational technology that controls equipment, environmental monitoring and packaging lines. Many of these systems are sensitive to disruption. Testing in these environments usually focuses on the boundaries: whether attackers could move from the corporate network into manufacturing networks, whether remote access for vendors is properly controlled and whether segmentation works as designed. Direct testing of control systems is typically limited, carefully scheduled and often done in test environments or during planned shutdowns.

Common Findings in Pharma Environments

• Weak segmentation between corporate, research and manufacturing networks.

• Remote access for vendors and partners without strong authentication or monitoring.

• Shared or generic accounts on lab systems and instruments.

• Unsupported operating systems on lab and manufacturing equipment.

• Excessive permissions to research data stores and file shares.

• Authorization flaws in clinical and partner portals.

• Cloud storage with overly broad access to research or trial data.

• Backups reachable from compromised accounts, weakening ransomware recovery.

For a structured approach to closing gaps, read our guide to penetration testing remediation.

How to Run Pharma Penetration Testing

1. Identify drivers: regulatory, partner, insurance and internal risk requirements.

2. Map critical systems and data: research IP, clinical data, quality and manufacturing systems.

3. Engage quality and operations: agree how validated and manufacturing systems will be handled.

4. Define scope and rules of engagement: targets, timing, safeguards and contacts.

5. Test: run external, internal, application, cloud and boundary testing as scoped.

6. Remediate and retest: fix findings by risk through change control and confirm the fixes work.

7. Report: share results with leadership, quality and partners as appropriate.

For testing phases in more detail, see our overview of penetration testing methodology.

Protecting Research and Trial Data During Testing

Testers may encounter confidential research or participant data while proving a weakness. Agree in the contract and rules of engagement that testers will access only what is needed to demonstrate impact, will not download research or clinical data beyond proof of access, will mask any sensitive data in reports and will securely delete working files at the end of the engagement. For multinational trials, consider data protection requirements in each country involved.

Choosing a Testing Partner

• Experience with pharmaceutical, biotech or other regulated life sciences companies.

• Understanding of GxP, data integrity and validated system requirements.

• Careful methods for testing manufacturing and operational technology boundaries.

• Qualified testers who perform manual testing, not just scans.

• Strict confidentiality and data handling commitments.

• Clear reports for IT, quality, leadership and partners, plus retesting.

Our guide to choosing a penetration testing company lists more questions to ask.

Cost of Pharma Penetration Testing

The cost of pharma penetration testing depends on the number of sites, research and clinical applications in scope, cloud platforms, manufacturing boundaries, validation requirements and reporting needs. A small biotech with cloud-based research tools may need a focused external, cloud and application test, while a global manufacturer with several plants and many partner connections needs a larger, phased program. For pricing factors, see penetration testing cost.

Common Mistakes to Avoid

• Treating a vulnerability scan as a penetration test.

• Testing validated systems without involving quality assurance.

• Ignoring the boundary between corporate and manufacturing networks.

• Leaving CRO, CMO and other partner connections out of scope.

• Failing to retest after fixes.

• Keeping results within IT instead of sharing them with quality and leadership.

Building a Year-Round Program

Security in pharma is a continuous effort. Combine annual pharma penetration testing with vulnerability management, multi-factor authentication, privileged access controls, vendor reviews, tested backups and incident response exercises that include manufacturing scenarios. Test again after major changes such as new research platforms, plant expansions, acquisitions or system upgrades. For continuous coverage, see our guides to annual penetration testing and continuous penetration testing.

Testing for Biotech Startups

Early-stage biotech companies often run almost entirely in the cloud, with small IT teams and many outside partners. They also face due diligence from investors, pharma partners and acquirers who want evidence that research data is protected. Focused pharma penetration testing covering cloud accounts, collaboration tools, research data stores and remote access can uncover the most serious risks at a manageable cost and give leadership a clear story to tell during partnering and fundraising. Repeating focused pharma penetration testing each year shows steady improvement as the company grows.

Ransomware and Business Continuity

Ransomware is one of the most disruptive threats for pharmaceutical companies because it can stop research, delay trials and halt production at the same time. A well-scoped pharma penetration testing engagement shows whether an attacker who gains a foothold through phishing or exposed remote access could reach domain administrator rights, research file shares, quality systems or the boundary to manufacturing networks. Use the results to strengthen administrator controls, segmentation, offline or immutable backups and recovery plans for critical GxP systems, including how validated systems will be restored and verified after an incident.

Cyber insurers and partners increasingly ask about these controls, so see our guide to penetration testing for cyber insurance.

Mergers, Acquisitions and Partnerships

Pharma companies frequently acquire smaller biotechs, license molecules and connect new partners to their networks. Each deal brings new systems, accounts and data flows. Testing an acquired company's environment before full integration helps avoid importing hidden risks, and testing new partner connections confirms that access is limited to what the partnership requires.

Frequently Asked Questions About Pharma Penetration Testing

What is pharma penetration testing?

Pharma penetration testing is an authorized security test of the research, clinical, manufacturing and business systems used by pharmaceutical and biotech companies.

Does 21 CFR Part 11 require penetration testing?

Part 11 does not name penetration testing, but it requires controls that protect electronic records and limit system access, and testing is one of the best ways to show those controls work.

Can validated GxP systems be penetration tested?

Yes, with careful planning. Testing is usually coordinated with quality assurance, documented under change control and often performed in qualified test environments.

Should manufacturing systems be included?

Usually the boundary between corporate and manufacturing networks is tested, while direct testing of control systems is limited and carefully scheduled.

How often should pharma companies run penetration tests?

At least once a year and after major changes, such as new research platforms, plant expansions, acquisitions or system upgrades.

Do partners ask for penetration test results?

Yes. Pharma partners, CROs, investors and acquirers often ask for testing evidence during due diligence and vendor reviews.

Final Thoughts

Pharma penetration testing helps pharmaceutical companies protect research, clinical data and production while supporting data integrity expectations. Scope testing around your most valuable data and critical operations, plan carefully for validated and manufacturing systems, fix and retest findings, and share results with the teams responsible for quality and risk.

To plan pharma penetration testing for your organization, explore Privaxi's healthcare and life sciences cybersecurity services.